Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-642,073
Closed -$12.2M 160
2023
Q2
$12.2M Hold
642,073
0.21% 115
2023
Q1
$9.78M Buy
+642,073
New +$8.37M 0.18% 116
2022
Q1
Sell
-716,670
Closed -$9.37M 140
2021
Q4
$9.37M Sell
716,670
-420,422
-37% -$6.65M 0.12% 114
2021
Q3
$22.3M Hold
1,137,092
0.29% 88
2021
Q2
$21.3M Sell
1,137,092
-131,447
-10% -$2.93M 0.29% 90
2021
Q1
$30M Buy
1,268,539
+399,539
+46% +$9.22M 0.45% 72
2020
Q4
$21.2M Buy
869,000
+194,000
+29% +$4.96M 0.32% 89
2020
Q3
$17.3M Buy
675,000
+100,000
+17% +$3.17M 0.34% 82
2020
Q2
$11.5M Buy
575,000
+225,000
+64% +$5.47M 0.25% 91
2020
Q1
$8.84M Hold
350,000
0.29% 89
2019
Q4
$9.2M Buy
+350,000
New +$9.74M 0.26% 80

Other funds holding ETNB

Eventide Asset Management's ETNB Position: Q3 2023 in Review

Eventide Asset Management sold out of 89bio (ETNB) in Q3 2023, closing a stake of 642,073 shares — an estimated $12.2M sold.

Eventide Asset Management first reported a position in ETNB in Q4 2019 and held it in 11 quarters. The position peaked at $30M in Q1 2021. 160 funds tracked by Wall St. Rank hold ETNB as of Q3 2023.

  • Eventide Asset Management reported no remaining 89bio position as of Q3 2023 after selling out during the quarter.
  • Eventide Asset Management sold 642,073 89bio shares in Q3 2023, an estimated $12.2M.
  • Eventide Asset Management first reported a position in 89bio in Q4 2019 and held it in 11 quarters.
  • Eventide Asset Management's 89bio position peaked at $30M in Q1 2021.
  • 160 funds tracked by Wall St. Rank held 89bio as of Q3 2023.

Based on Eventide Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.